$MIRM News
Last published 1d ago
- 1d agoMIRMMirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLDBusiness WireFOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD
- 1w agoMIRMMirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update - MIRUM PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon, and welcome to Mirim Pharmaceuticals' third quarter 2026 earnings conference call. My name is Joel, and I will be your operator today. All lines are currently in a listen-only mode, and there will be an o
- 1w agoMIRMMirum Pharmaceuticals, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoMIRMMirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026Business WireMirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it will report third quarter 2026 financial results on November 3, 2026. Mirum will also host a conference call to discuss
- 2w agoMIRMMirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans ProgressivaBusiness Wire- Zilurgisertib reduced total HO lesion volume and improved clinician-assessed joint mobility; no zilurgisertib-treated patients developed new HO lesions - Mirum plans to submit an sNDA in H1 2027 to expand the
- 3w agoMIRMMirum Pharmaceuticals to Participate in Upcoming Investor ConferencesBusiness WireMirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it will participate in the following upcoming investor conferences: Wolfe Research Healthcare Conference 2026: Tuesday,
- 3w agoMIRMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireMirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that on October 9, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of
- 1mo agoMIRMMirum Pharmaceuticals Business Update Call - MIRUM PHARMACEUTICALS INCEarnings Call TranscriptsGood morning, and welcome to the Merham Pharmaceuticals Business Update Call. My name is Kelsey, and I will be your operator today. All lines are currently in a listen-only mode, and there will be an opportunity for Q&A
- 1mo agoMIRMMirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver DiseasesBusiness Wire- Maralixibat demonstrated a statistically significant reduction in cholestatic pruritus compared with placebo (p=0.0004), and a 69% reduction in serum bile acids versus placebo (p<0.0001) - In patients with
- 1mo agoMIRMMirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver DiseasesBusiness WireMirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, October 12, 2026 at 8:30 a.m. ET/5:30 a.m. PT to share topline results from the
- 1mo agoMIRMMirum Pharmaceuticals Business Update Call - MIRUM PHARMACEUTICALS INCEarnings Call TranscriptsGood morning, and welcome to the Merum Pharmaceuticals Business Update Call. My name is Hilary, and I will be your operator today. All lines are currently in a listen-only mode, and there will be an opportunity for Q&A a
- 1mo agoMIRMMirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta VirusBusiness Wire– Phase 3 primary endpoint (virologic response and ALT normalization) achieved in both dose arms at Week 24 – 48-week data from Phase 2b portion of AZURE-1 demonstrate deepening viral suppression and increased rates
- 1mo agoMIRMMirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026Business WireMirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, September 28, 2026 at 8:30 a.m. ET/5:30 a.m. PT to share topline results from the
- 1mo agoMIRMINCYMirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans ProgressivaBusiness Wire-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP -Atebrioz expected to be available in the United States in October
- 1mo agoMIRMMorgan Stanley 24th Annual Global Healthcare Conference - MIRUM PHARMACEUTICALS INCEarnings Call TranscriptsAll right. Hello, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Oltz, one of the biotech analysts here. It's my pleasure to introduce Chris Peets, CEO from Merum Pharmac
- 1mo agoMIRMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireMirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that on September 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of
- 2mo agoMIRMMirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical OfficerBusiness WireMirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced the appointment of Rob Myers, M.D., as Chief Medical Officer, effective September 21, 2026. Dr. Myers will join the company’s
- 3mo agoMIRMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireMirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that on August 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of
- 3mo agoMIRMMirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - MIRUM PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon, and welcome to Merum Pharmaceuticals' second quarter 2026 earnings conference call. My name is Alexandra, and I will be your operator today. All lines are currently in a listen-only mode, and there will b
- 3mo agoMIRMMirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business UpdateBusiness Wire- Q2 2026 net product sales of $176 million - 2026 net product sales guidance increased to $680 million to $700 million - Volixibat granted Breakthrough Therapy and Orphan Drug Designations for cholestatic pruritus
- 3mo agoMIRMMirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026Business WireMirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it will report second quarter 2026 financial results on August 5, 2026. Mirum will also host a conference call to discuss
- 4mo agoMIRMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireMirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that on July 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of
- 5mo agoINCYMIRMMirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans ProgressivaBusiness Wire- Cohort 1 results presented at ENDO 2026 demonstrate meaningful reductions in total heterotopic ossification (HO) lesion volume, new HO lesions and flare activity in adolescents and adults with FOP - U.S. Food and
- 5mo agoMIRMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireMirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that on June 10, 2026, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of
- 5mo agoINCYMIRMMirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026Business Wire- Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP) Mirum Pharmaceuticals, Inc.
- 5mo agoMIRMMirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026Business Wire- Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC) - Late-breaking Phase 2b AZURE-1 results demonstrate
- 5mo agoMIRMMirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026Business Wire- Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC) - Late-breaking Phase 2b AZURE-1 results demonstrate
- 5mo agoMIRMApproval of Cholbam, Nda #205750 (Labeling)FDA Approved DrugsApproval Date: 05/21/2026; Drug Name: Cholbam, Nda #205750; Active Ingredients: CHOLIC ACID; Company: Mirum; Submission Status: Approval; Submission Classification: Labeling; Application Number: 205750
- 6mo agoMIRMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireMirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that on May 11, 2026, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of
- 6mo agoMIRMMirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible NotesBusiness WireMirum Pharmaceuticals, Inc. ("Mirum") (NASDAQ:MIRM), a leading rare disease company, today announced the pricing of its offering of $600.0 million aggregate principal amount of 0.00% convertible senior notes due 2032
- 6mo agoMIRMMirum Pharmaceuticals Announces Proposed Convertible Senior Notes OfferingBusiness WireMirum Pharmaceuticals, Inc. ("Mirum") (NASDAQ:MIRM), a leading rare disease company, today announced its intention to offer, subject to market conditions and other factors, $600.0 million aggregate principal amount of
- 6mo agoMIRMMirum Pharmaceuticals to Participate in Upcoming Investor ConferencesBusiness WireMirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it will participate in the following upcoming investor conferences: H.C. Wainwright 4th Annual BioConnect Investor
- 6mo agoMIRMMirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business UpdateBusiness Wire- Q1 2026 net product sales of $159.9 million - 2026 net product sales guidance increased to $660 to $680 million - Volixibat VISTAS Phase 2b study met primary endpoint - Brelovitug Phase 2b portion of AZURE-1
- 6mo agoMIRMMirum Pharmaceuticals Business Update Call - MIRUM PHARMACEUTICALS INCEarnings Call TranscriptsGood morning, and welcome to Merum Pharmaceuticals Business Update Call. My name is Ben, and I will be your operator today. All lines are currently in a listen-only mode, and there will be an opportunity for Q&A after ma
- 6mo agoMIRMMirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing CholangitisBusiness Wire- Statistically significant and clinically meaningful 2.72 point reduction from baseline and 1.64 point placebo-adjusted (p=<0.0001) reduction in primary endpoint of cholestatic pruritus - Pre-NDA meeting with the
- 6mo agoMIRMMirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026Business WireMirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, May 4, 2026 at 8:30 a.m. ET/5:30 a.m. PT to share topline results from the VISTAS
- 6mo agoMIRMMirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026Business WireMirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it will report first quarter 2026 financial results on May 6, 2026. Mirum will also host a conference call to discuss the
- 6mo agoMIRMMirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta VirusBusiness Wire-Primary endpoint (virologic response and ALT normalization) achieved in both dose arms at Week 24 -Favorable safety and tolerability profiles observed - Full results to be presented in a late-breaking poster
- 7mo agoMIRMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireMirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that on April 10, 2026, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of
- 8mo agoMIRMMirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver DiseasesBusiness Wire- Study designed to support potential label expansion into additional settings of cholestatic pruritus - Topline data expected in Q4 2026 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company,
- 8mo agoMIRMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireMirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that on March 11, 2026, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of
- 8mo agoMIRMMirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta VirusBusiness Wire- Phase 3 AZURE-1 enrollment complete - Phase 3 AZURE-4 screening complete - Topline AZURE-1 and AZURE-4 results expected in 2H 2026 - AZURE-1 and AZURE-4 to form the basis of Mirum's U.S. BLA Submission Mirum
- 8mo agoMIRMMirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update - MIRUM PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon, and welcome to Merham Pharmaceuticals' fourth quarter and full year 2025 conference call. My name is Elliot, and I'll be your operator today. All lines are currently in listen-only mode, and there will be
- 8mo agoMIRMMirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business UpdateBusiness Wire- 2025 net product sales of $521 million - 2026 expected global net product sales of $630 million to $650 million - Volixibat VISTAS study in PSC topline data expected Q2 2026 - LIVMARLI® EXPAND study in
- 8mo agoMIRMMirum Pharmaceuticals to Participate in Upcoming Investor ConferencesBusiness WireMirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it will participate in the following upcoming investor conferences: TD Cowen's 46th Annual Health Care Conference:
- 8mo agoMIRMMirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026Business WireMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report fourth quarter and year-end 2025 financial results on February 25, 2026. Mirum will also host a conference call to discuss the fourth quarter
- 9mo agoMIRMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that on February 10, 2026, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to
- 9mo agoMIRMMirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille SyndromeBusiness Wire- Tablet authorization builds upon established use of LIVMARLI oral solution in Canada Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that Health Canada has authorized the
- 9mo agoMIRMMirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)Business Wire- Authorization includes oral solution and tablet formulation to support flexible dosing Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that Health Canada has authorized
- 10mo agoMIRMMirum Pharmaceuticals Announces Additional Private Placement Financing With TCGXBusiness WireMirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it has entered into a subscription agreement with entities associated with TCGX, an institutional investor, for a private